Nov 23,2021

Start of the first human clinical trials for K’Watch Glucose

PKvitality, a French company specializing in health and sports "bio-wearables", announces the start of a clinical study to determine the accuracy of K'Watch Glucose . This study is being conducted with the AMCR Institute, a clinical research center specializing in diabetes and obesity with world-renowned expertise in metabolic medical devices.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Nov 24,2021

Insulet to Present at Nasdaq’s 45th Investor Conference

Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the virtual 45th Nasdaq Investor Conference on Friday, December 3, 2021 at 11:30 a.m. (Eastern Time).

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Nov 24,2021

Precision Health Company January AI Expands Availability Of Its ‘Season Of Me’ Program On BestBuy.Com

January AI announced it will be available through BestBuy.com and will  give users confidence in their approach to health & wellness. The ‘Season of Me’ program takes personalized user data and combines it with January’s proprietary AI to unlock tangible insights into how their body responds to food and activity.

COLLABORATION PARTNERSHIP

#product & service

View Analyst & Ambassador Comments
Go to original news
Nov 30,2021

AWS Supports Roche In Harnessing The Power Of Health Data At Scale

Amazon Web Services (AWS), an Amazon.com, Inc. company announced that the Roche Group is using AWS for the majority of its cloud workloads to help Roche extract greater value from its health data. The company uses AWS capabilities in high performance computing, analytics, machine learning, database, storage, and security to accelerate drug discovery and development, and process health data at scale to deliver high-quality, individually tailored care. For instance, Roche built and runs its mySugr app on AWS to securely aggregate and analyze data such as blood glucose measurements for patients with diabetes.

COLLABORATION PARTNERSHIP

#r&d

#mobile app

View Analyst & Ambassador Comments
Go to original news
Dec 01,2021

Bigfoot Clinic Hub™ Puts Critical Data At Fingertips of Health Care Professionals

Since launching in late summer 2021, the innovative Bigfoot UnityTM Diabetes Management Program and its Bigfoot Clinic HubTM are demonstrating that technology can help transform how health care professionals (HCPs) manage their patient populations on multiple daily injections (MDI) of insulin. “The traditional treatment plan for people with Type 1 or Type 2 diabetes on MDI therapy is simply not working for health care professionals or their patients,” said Dr. Jim Malone, chief medical officer for Bigfoot Biomedical. “We’ve created a first-of-its-kind, HCP-centered solution that supports clinicians to efficiently deliver proactive care with a much-needed level of simplicity and convenience to facilitate both patient adherence and practice implementation.”

PRODUCT

#telehealth

#mobile app

View Analyst & Ambassador Comments
Go to original news
Dec 02,2021

Tandem Diabetes Care Announces Expansion of Senior Leadership Team

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointments of Rick Carpenter as Chief Technical Officer, Libba Sapitsky as Senior Vice President, Customer Care, and Rizwan Pervez as Senior Vice President, Quality and Regulatory.

View Analyst & Ambassador Comments
Go to original news
Dec 02,2021

Digital Insulin Management Company Hygieia Closes on $17 Million Series B Investment Round

Funding will enable expansion of company’s AI-driven d-Nav technology, which automates real-time insulin dose recommendations for people with type 2 diabetes. Hygieia, a digital health company for insulin management, has closed on an initial $17 million Series B investment round, led by Israeli venture capital firm Firstime Ventures, and with participation from existing investors.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Dec 02,2021

DarioHealth Announces Two New Contracts within the Employer and Provider Markets

DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced new contracts today to provide its highly personalized digital therapeutics beginning in the first quarter of 2022. The new clients include a regional employer contract for behavioral health, and a strategic partnership in the provider market that will allow Dario solutions to be sold through a network of practices across the United States. The two new contracts mark a key milestone for Dario, bringing its total signed clients to date to more than 50.

#dtx

View Analyst & Ambassador Comments
Go to original news
Dec 03,2021

Mobile App Interventions to Improve Medication Adherence Among Type 2 Diabetes Mellitus Patients: A Systematic Review of Clinical Trials

Medication adherence in type 2 diabetes mellitus (T2DM) patients is often suboptimal resulting in complications. There has been a growing interest in using mobile apps for improving medication adherence.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Dec 07,2021

Nemaura Medical Completes Initial Shipment of CGM Devices to UK Licensee

emaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces that it has completed its initial shipment of sugarBEAT® continuous glucose monitor (CGM) devices to its UK licensee, MySugarWatch Limited (“MySugarWatch”), previously DB Ethitronix Limited.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES